EXHIBIT 99.1 Financial Results "Once again, we had a record number of new Korlym® prescribers and a record number of patients receiving Korlym in the quarter. Physicians are increasingly aware of hypercortisolism's true prevalence and the poor health outcomes for patients who go untreated. Screening is becoming more common and the number of patients receiving appropriate care continues to increase. We are confident that our Cushing's syndrome business will grow for many years," said Joseph K. Belanoff, M.D. ...

Company Overview - Corcept Therapeutics (CORT) shares increased by 13.6% to close at $69.90, with trading volume significantly higher than usual, contributing to a total gain of 22.1% over the past four weeks [1][2] Drug Development and Market Position - The company submitted a new drug application (NDA) for relacorilant, a selective cortisol modulator aimed at treating endogenous hypercortisolism (Cushing's syndrome), which could expand its market reach beyond the existing treatment Korlym (mifepristone) [2] - Korlym has seen strong demand in recent quarters, indicating a solid market position for Corcept [2] Financial Performance Expectations - Corcept is projected to report quarterly earnings of $0.37 per share, reflecting a year-over-year increase of 32.1%, with revenues expected to reach $195.88 million, up 44.7% from the previous year [3] - The consensus EPS estimate for Corcept has remained stable over the last 30 days, suggesting that the stock's price movement may not sustain without changes in earnings estimate revisions [4] Industry Context - Corcept is classified under the Zacks Medical - Drugs industry, where Aurinia Pharmaceuticals (AUPH) is another player, having closed 1.7% lower at $8, with a return of -9.4% over the past month [4] - Aurinia's consensus EPS estimate has also remained unchanged, projected at $0.05, which represents a significant year-over-year increase of 126.3% [5]

Core Viewpoint - Corcept Therapeutics (CORT) has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive outlook for its stock price driven by an upward trend in earnings estimates [1][3]. Earnings Estimates and Stock Price Correlation - The Zacks rating system emphasizes the importance of changing earnings estimates, which are strongly correlated with stock price movements, particularly influenced by institutional investors [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations for stocks, prompting institutional buying or selling actions that affect stock prices [4]. Recent Performance and Projections - For the fiscal year ending December 2024, Corcept is projected to earn $1.35 per share, reflecting a 43.6% increase from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for Corcept has risen by 14.5%, indicating a positive trend in earnings expectations [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of Corcept to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting competent advisors before making any financial decisions, particularly in the context of investments in complex instruments like cryptocurrencies and CFDs [1]. Group 1 - The website provides general news, personal analysis, and third-party content intended for educational and research purposes [1]. - It explicitly states that the information does not constitute any recommendation or advice for investment actions [1]. - Users are advised to perform their own research and consider their financial situation before making decisions [1]. Group 2 - The website includes information about high-risk financial instruments, including cryptocurrencies and CFDs, which are complex and can lead to significant financial losses [1]. - It highlights the necessity for users to understand how these instruments work and the associated risks before investing [1]. - The content warns that the information may not be real-time or accurate, and prices may be provided by market makers rather than exchanges [1].

Core Viewpoint - U.S. stock markets are experiencing significant volatility due to concerns over inflation, interest rates, and elevated treasury yields [1][2] Market Conditions - The Trump administration's protectionist tariff policies are causing investor anxiety [2] - A strong U.S. economy, resilient labor market, and persistent inflation are raising doubts about potential interest rate cuts this year [2] Stock Performance - A selection of stocks has demonstrated price strength, particularly those on a recent bull run, indicating potential for continued momentum [3] - Five highlighted stocks include OppFi Inc. (OPFI), Corcept Therapeutics Inc. (CORT), DXP Enterprises Inc. (DXPE), Perpetua Resources Corp. (PPTA), and Graham Corp. (GHM) [3] Stock Screening Criteria - Stocks must show a percentage change in price greater than zero over the last four weeks [5] - Stocks must have a percentage change in price greater than 10% over the last twelve weeks [5] - Zacks Rank 1 (Strong Buy) is a key indicator of potential outperformance [6] - Average broker rating of 1 indicates strong future performance expectations [6] - Stocks must be trading at a minimum price of $5 [6] - Current price must be more than 85% of the 52-week high-low range [7] Individual Stock Analysis - **OppFi Inc. (OPFI)**: Stock price increased by 81.2% in the past four weeks, with expected earnings growth of 16.3% for the current year [10] - **Corcept Therapeutics Inc. (CORT)**: Stock price rose by 20.4% in the past four weeks, with an expected earnings growth rate of 36.4% for the current year [13] - **DXP Enterprises Inc. (DXPE)**: Stock price climbed by 19.8% in the past four weeks, with expected earnings growth of 5.9% for the current year [15] - **Perpetua Resources Corp. (PPTA)**: Stock price advanced by 6.7% in the past four weeks, with expected earnings growth of 25.4% for the current year [16] - **Graham Corp. (GHM)**: Stock price increased by 0.5% in the past four weeks, with expected earnings growth of over 100% for the current year [18]

Core Insights - Growth investors seek stocks with above-average financial growth, but identifying such stocks is challenging due to inherent risks and volatility [1] - The Zacks Growth Style Score simplifies the identification of promising growth stocks, with Corcept Therapeutics (CORT) currently recommended due to its favorable Growth Score and top Zacks Rank [2] Earnings Growth - Earnings growth is crucial for investors, with double-digit growth preferred as an indicator of strong prospects [4] - Corcept's projected EPS growth is 36.4% this year, significantly higher than the industry average of 16.6% [5] Asset Utilization - The asset utilization ratio, or sales-to-total-assets (S/TA) ratio, is an important metric for growth investing [6] - Corcept's S/TA ratio is 0.91, indicating it generates $0.91 in sales for every dollar in assets, compared to the industry average of 0.42, showcasing superior efficiency [6] Sales Growth - Sales growth is another critical factor, with Corcept expected to achieve a sales growth of 12.8% this year, outpacing the industry average of 9.5% [7] Earnings Estimate Revisions - Trends in earnings estimate revisions correlate strongly with near-term stock price movements [8] - Corcept's current-year earnings estimates have been revised upward, with the Zacks Consensus Estimate increasing by 0.1% over the past month [9] Conclusion - Corcept has achieved a Growth Score of A and a Zacks Rank 2, positioning it well for potential outperformance, making it an attractive option for growth investors [11]

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Corcept Therapeutics Inc. related to self-dealing, which may entitle shareholders to damages and corporate governance reforms [1]. Group 1 - The investigation focuses on whether certain officers and directors of Corcept Therapeutics Inc. have engaged in self-dealing that could harm shareholder interests [1]. - Shareholders are encouraged to contact Kuehn Law for a free consultation regarding their rights and potential claims [2]. - The law firm emphasizes the importance of shareholder participation in maintaining the integrity of financial markets [3].

Company Performance - Corcept Therapeutics (CORT) shares have increased by 16.2% over the past month and reached a new 52-week high of $62.98 [1] - Year-to-date, the stock has gained 23.6%, outperforming the Zacks Medical sector, which declined by 2.1%, and the Zacks Medical - Drugs industry, which fell by 7.9% [1] Earnings and Revenue - Corcept has consistently exceeded earnings expectations, reporting an EPS of $0.41 against a consensus estimate of $0.27 in its last earnings report on October 30, 2024, and beating revenue estimates by 6.07% [2] - For the current fiscal year, Corcept is projected to earn $1.84 per share on revenues of $689.04 million, with a year-over-year earnings growth of 36.44% [3] - For the next fiscal year, earnings are expected to rise to $2.84 per share on revenues of $777.04 million, reflecting a year-over-year change of 12.77% [3] Valuation Metrics - Corcept's current valuation metrics indicate a premium, trading at 33.8X current fiscal year EPS estimates compared to the peer industry average of 20.7X [6] - On a trailing cash flow basis, the stock trades at 65X versus an average of 8X for its peer group, suggesting it is not positioned in the top echelon from a value perspective [6] Zacks Rank and Style Scores - Corcept holds a Zacks Rank of 2 (Buy) due to favorable earnings estimate revisions from analysts, meeting the criteria for potential gains [7] - The stock has a Value Score of C, a Growth Score of A, and a Momentum Score of C, resulting in a combined VGM Score of B [6][7] Industry Comparison - AMNEAL PHARMACEUTICALS, INC. (AMRX) is a notable peer with a Zacks Rank of 2 (Buy) and strong style scores across Value, Growth, and Momentum [8] - AMRX has also shown strong earnings performance, beating consensus estimates by 23.08% last quarter, with projected earnings of $0.70 per share on revenues of $2.77 billion for the current fiscal year [9] - The Medical - Drugs industry is positioned in the top 35% of all industries, indicating favorable conditions for both CORT and AMRX [10]

Core Insights - Chuck Jones has extensive experience in equity analysis and investment management, with a focus on technology and life sciences sectors [1] - He has successfully developed strategies for wealth management targeting technology executives and private equity partners [1] - Jones has a strong track record of outperforming industry benchmarks through financial modeling and direct engagement with company leadership [1] Group 1: Career Background - Chuck Jones has a total of twelve years as an equity analyst and sixteen years in various roles at IBM [1] - He has held significant positions at Northern Trust and Atlantic Trust Private Wealth Management, focusing on technology holdings [1] - His early career included a lead analyst role for Internet Security Software at Smith Barney, where he authored comprehensive industry reports [1] Group 2: Skills and Achievements - Jones utilized extensive financial modeling and industry contacts to achieve superior performance over six consecutive years [1] - He has been recognized with multiple sales awards during his tenure at IBM, including a President's award [1] - His educational background includes a B.S. in Industrial Engineering from Stanford University and a Postgraduate Diploma in Economics from the University of Sussex [1]

Core Insights - Corcept Therapeutics announced data from the phase II DAZALS study evaluating dazucorilant for treating amyotrophic lateral sclerosis (ALS) [1] - The study did not meet its primary endpoint, leading to a decline in Corcept's shares in pre-market trading [2] - Year-to-date, Corcept's shares have increased by 85%, contrasting with a 4.6% decline in the industry [3] Study Details - The DAZALS study was a double-blind, placebo-controlled trial assessing two doses of dazucorilant (150 mg and 300 mg) [1] - Patients treated with dazucorilant experienced significantly more gastrointestinal upset compared to the placebo group [4] - An open-label, long-term extension study will continue, with overall survival data expected in March next year [5] Regulatory and Pipeline Updates - The FDA has granted Fast Track Designation to dazucorilant for ALS treatment [7] - Corcept's lead pipeline candidate, relacorilant, is in phase III of the GRACE study for Cushing's syndrome [8] - An NDA for relacorilant in Cushing's syndrome is anticipated to be submitted shortly [10] Additional Studies - Relacorilant is also being evaluated in combination with other drugs for various cancer indications, including a phase III study for platinum-resistant ovarian cancer [11]